1. Glutathione S-Transferase T1, O1 and O2 Polymorphisms Are Associated with Survival in Muscle Invasive Bladder Cancer Patients.
- Author
-
Djukic, Tatjana I., Savic-Radojevic, Ana R., Pekmezovic, Tatjana D., Matic, Marija G., Pljesa-Ercegovac, Marija S., Coric, Vesna M., Radic, Tanja M., Suvakov, Sonja R., Krivic, Biljana N., Dragicevic, Dejan P., and Simic, Tatjana P.
- Subjects
- *
GLUTATHIONE transferase , *CANCER invasiveness , *BLADDER cancer , *GLUTATHIONE synthase , *GENETIC polymorphisms , *MUSCLES - Abstract
Objective: To examine the association of six glutathione transferase (GST) gene polymorphisms (GSTT1, GSTP1/rs1695, GSTO1/rs4925, GSTO2/rs156697, GSTM1, GSTA1/rs3957357) with the survival of patients with muscle invasive bladder cancer and the genotype modifying effect on chemotherapy. Patients and Methods: A total of 105 patients with muscle invasive bladder cancer were included in the study. The follow-up lasted 5 years. The effect of GSTs polymorphisms on predicting mortality was analyzed by the Cox proportional hazard models, while Kaplan-Meier analysis was performed to assess differences in survival. Results: GSTT1 active, GSTO1 Asp140Asp or GSTO2 Asp142Asp genotypes were independent predictors of a higher risk of death among bladder cancer patients (HR = 2.5, P = 0.028; HR = 2.9, P = 0.022; HR = 3.9, P = 0.001; respectively) and significantly influenced the overall survival. There was no association between GSTP1, GSTM1 and GSTA1 gene variants with overall mortality. Only GSTO2 polymorphism showed a significant effect on the survival in the subgroup of patients who received chemotherapy (P = 0.006). Conclusion: GSTT1 active genotype and GSTO1 Asp140Asp and GSTO2 Asp142Asp genotypes may have a prognostic/pharmacogenomic role in patients with muscle invasive bladder cancer. [ABSTRACT FROM AUTHOR]
- Published
- 2013
- Full Text
- View/download PDF